TORONTO – OCT. 27, 2015 – Two of Ontario’s innovative nuclear sector companies are once again building on their strong partnership and respective strengths to create a new, long-term supply of an important cancer-treating isotope, Cobalt-60, that will benefit healthcare patients in Canada and around the world.

Nordion, a standalone business within Sterigenics International, and Bruce Power announced today that they have executed a Memorandum of Understanding (MOU) for the supply of High Specific Activity (“HSA”) Cobalt-60, also referred to as medical-grade Cobalt. This type of Cobalt-60 is produced in a limited number of nuclear reactors globally and used in radiation-based treatment of cancer and other diseases in Canada and around the world.

“With limited supply available for the market, Nordion is acutely aware of how important it is, for our customers and for patients globally, that we secure a new long-term supply of medical-grade Cobalt,” said Scott McIntosh, President, Gamma Technologies & Corporate Services, Nordion. “Securing a new supply is a key milestone for both companies. We’re using promising new technology in Bruce Power’s reactors, adding to the contribution they will make through Ontario’s Long Term Energy Plan.
Ontario’s Long Term Energy Plan announced in December 2013, has identified a role for nuclear power in Ontario as part of a balanced, modern and clean electricity system. The role of nuclear power also includes medical applications. For over six decades, Nordion’s supply of medical-grade Cobalt has come primarily from the National Research Universal (NRU) reactor at Chalk River, Ontario. Recognizing that in a few years the NRU reactor will reach end of life, this MOU will lead to the development of a novel approach to create a new source of supply from Bruce Power building on existing technology and practices.

“While Bruce Power is mostly known for generating electricity, we are very proud of the work we do with Nordion. From our Bruce B facility, we currently supply them with Cobalt-60 that is used to sterilize medical supplies keeping hospitals around the world clean and safe,” said Duncan Hawthorne, President and Chief Executive Officer, Bruce Power. “This MOU builds on our strong relationship and recognizes our shared desire to develop a stable, additional supply source for this important isotope,” added Hawthorne.

Ontario not only has a nuclear industry that is internationally recognized but it’s also home to many globally-respected healthcare institutions and suppliers of important technologies and support services.

More HCB News